Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxymetazoline is a direct-acting sympathomimetic and imidazole derivative that acts as a potent agonist at alpha-1A adrenergic receptor and alpha-2 adrenergic receptor. It is primarily used as a topical decongestant for the temporary relief of nasal congestion caused by colds or allergies and for the treatment of facial erythema associated with rosacea. Oxymetazoline is also used in ophthalmic preparations to relieve eye redness and in topical formulations to treat acquired blepharoptosis (drooping eyelid). Its mechanism involves vasoconstriction of dilated arterioles through stimulation of adrenergic receptors in vascular smooth muscle. This reduces blood flow and swelling in mucosal tissues. The drug provides rapid relief from congestion with effects lasting up to 12 hours after intranasal administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxymetazoline.